Drug Interaction:
Drug lab interactions-
Possibilty of a false positive HIV test with ELISA assay, a confirmatory western blot test would be
expected to be negative.
Enfluviride has not been studied in non-HIV infected individuals
Indication:
HIV infection
Adverse Reaction:
Adverse reactions-
Infections - herpes simplex 4% influenza 3% sinusitis 6% skin papilloma 4%
GI - constipation 3% upper abdominal pain 2% pancreatitis 2%
Hematologic - lymphadenopathy 2%
Musculoskeletal - myalgia 4%
Ophthalmic - conjuntivitis 2%
Respiratory - cough 7%
Miscellaneous - anorexia 2% decreased appetite 6% decreased weight 6%
influenzal like illness 2%
Contra-Indications:
Hypersensitivity to enfuviride or its components
Special precautions-
Local site reactions- most common adverse reactions associated with enfuvirtide use
Pneumonia- Occured in treated subjects, Risk factors for pneumonia include low initial
CD4 count, high initial viral load,IV drug use, smoking, and history of lung disease
Hazardous reactions- patientsexperiencing dizziness while taking enfuvirtide, should be
adviced to talk to their doctor before driving or operating machinery
Pregnancy - the drug should be used during pregnancy only if clearly needed.
Lactation- mothers should be instructed not to breast feed if they receiving enfuvirtide
Children- safety for use in pediatric patients below 6 years of age have not been established
Elderly- Adequate clinical stidies not done in elderly patients above 65 years of age.
Excercise caution while administering to patients above 65 years of age.
Dosages/ Overdosage Etc:
Indication-
HIV infection
Dosage- Adults - 90mg ( 1ml ) twice daily injected SC into the upper arm , anterior thigh
or abdomen. Each injection should be given at a site different from the preceeding
injection site, and only where there is no current injection site reactionfrom the earlier
dose.
Enfuvirtide should not be injected into moles, scar tissuue, bruises, or the navel.
Children- no data available to establish dose recommendation of pediatric patients
below the age of 6 years
In pediatric patients 6 years through 16 years of age the recommended dose of 90mg
twice daily injected into upper arn, anterior thigh or abdomen.
Each injection should be given at a site different from the preceeding injection site,
and only where there is no current injection site reactionfrom the earlier dose.
Patient Information:
1. Patients should be informed that injection site reaction occur commonly and made aware of
the injection instructions
2, Patients should report promptly about the reactions, anf for signs or symptoms of cellilitis
or local infection.
3. Patients should be aware about the increased rate of bacterial pneumonia that may occur
4. Patients should be made aware of the hypersensitivity reactions and they should report
promptly, if rash ,fever, nausea, vomiting, chills, rigors, hypotension, and elevated serum
liver transaminse occur
5. Patients should be aware that enfuvirtide is not a cure for HIV infections and patients may
continue to contact illness associated with HIV infection.
6. Patients should inform their doctor if they are pregnant or plan to become pregnant
while taking this medication
7. Patients , if they experience dizzines while taking taking this medication, should nor drive
or operate any hazardous machinery.
Pregnancy and lactation:
Pregnancy -
The drug should be used during pregnancy only if clearly needed.
Lactation- Mothers should be instructed not to breast feed if they receiving enfuvirtide
Children-
Safety for use in pediatric patients below 6 years of age have not been established
Elderly-
Adequate clinical stidies not done in elderly patients above 65 years of age.
Excercise caution while administering to patients above 65 years of age.
About Us